Sample Size Computations for PK/PD Population Models

We describe an accurate, yet simple and fast sample size computation method for hypothesis testing in population PK/PD studies. We use a first order approximation to the nonlinear mixed effects model and chi-square distributed Wald statistic to compute the minimum sample size to achieve given degree of power in rejecting a null hypothesis in population PK/PD studies. The method is an extension of Rochon’s sample size computation method for repeated measurement experiments. We compute sample sizes for PK and PK/PD models with different conditions, and use Monte Carlo simulation to show that the computed sample size retrieves the required power. We also show the effect of different sampling strategies, such as minimal, i.e., as many observations per individual as parameters in the model, and intensive on sample size. The proposed sample size computation method can produce estimates of minimum sample size to achieve the desired power in hypothesis testing in a greatly reduced time than currently available simulation-based methods. The method is rapid and efficient for sample size computation in population PK/PD study using nonlinear mixed effect models. The method is general and can accommodate any type of hierarchical models. Simulation results suggest that intensive sampling allows the reduction of the number of patients enrolled in a clinical study.

[1]  A. Wald Tests of statistical hypotheses concerning several parameters when the number of observations is large , 1943 .

[2]  J Rochon,et al.  Application of GEE procedures for sample size calculations in repeated measures experiments. , 1997, Statistics in medicine.

[3]  France Mentré,et al.  Optimization of Individual and Population Designs Using Splus , 2003, Journal of Pharmacokinetics and Pharmacodynamics.

[4]  K. Lui Sample sizes for repeated measurements in dichotomous data. , 1991, Statistics in medicine.

[5]  K. Lui Sample Size Determination for Repeated Measurements in Bioequivalence Test , 1997, Journal of Pharmacokinetics and Biopharmaceutics.

[6]  Dongwoo Kang,et al.  A sample size computation method for non‐linear mixed effects models with applications to pharmacokinetics models , 2004, Statistics in medicine.

[7]  L Aarons,et al.  Population pharmacokinetics of tobramycin. , 1989, British journal of clinical pharmacology.

[8]  D. Abernethy,et al.  Verapamil pharmacodynamics and disposition in young and elderly hypertensive patients. Altered electrocardiographic and hypotensive responses. , 1986, Annals of internal medicine.

[9]  M A Schork,et al.  Sample sizes in the multivariate analysis of repeated measurements. , 1986, Biometrics.

[10]  Mats O. Karlsson,et al.  Assessment of Type I Error Rates for the Statistical Sub-model in NONMEM , 2002, Journal of Pharmacokinetics and Pharmacodynamics.

[11]  S. Akselrod,et al.  Hemodynamic regulation in SHR: investigation by spectral analysis. , 1987, The American journal of physiology.

[12]  L Pronzato,et al.  Optimal experiment design for nonlinear models subject to large prior uncertainties. , 1987, The American journal of physiology.

[13]  D. Bloch,et al.  Sample size requirements and the cost of a randomized clinical trial with repeated measurements. , 1986, Statistics in medicine.

[14]  S. Gupta,et al.  Population analyses of sustained‐release verapamil in patients: Effects of sex, race, and smoking , 2003, Clinical pharmacology and therapeutics.

[15]  G. Segre,et al.  Kinetics of interaction between drugs and biological systems. , 1968, Il Farmaco; edizione scientifica.

[16]  Eric R. Ziegel,et al.  Practical Nonparametric and Semiparametric Bayesian Statistics , 1998, Technometrics.

[17]  Claudio Cobelli,et al.  Identifiability of compartmental systems and related structural properties , 1979 .

[18]  S. Chow,et al.  On Sample Size Calculation in Bioequivalence Trials , 2001, Journal of Pharmacokinetics and Pharmacodynamics.

[19]  W. Cumberland,et al.  Sample size requirement for repeated measurements in continuous data. , 1992, Statistics in medicine.

[20]  Varun Garg,et al.  Comparison of four basic models of indirect pharmacodynamic responses , 1993, Journal of Pharmacokinetics and Biopharmaceutics.

[21]  France Mentré,et al.  Robust Optimal Design for the Estimation of Hyperparameters in Population Pharmacokinetics , 1998, Journal of Pharmacokinetics and Biopharmaceutics.

[22]  J. Jacquez,et al.  Numerical parameter identifiability and estimability: Integrating identifiability, estimability, and optimal sampling design , 1985 .

[23]  D Verotta,et al.  Concepts, properties, and applications of linear systems to describe distribution, identify input, and control endogenous substances and drugs in biological systems. , 1996, Critical reviews in biomedical engineering.